Cagrilintide

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin that regulates satiety. It is being developed by Novo Nordisk, both as monotherapy and in combination with semaglutide (CagriSema). Phase 2 trials have shown promising weight loss results.

PubMed results: 69 · Human studies: 42 · Animal studies: 45

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Subcutaneous Injection — standard range 0.3-4.5 mg weekly, Once weekly

~6-8 days (moderate confidence)

• Body weight reduction (Moderate clinical): Phase 2 trials of cagrilintide monotherapy and the cagrilintide–semaglutide combination (CagriSema) demonstrated clinically meaningful reductions in body weight in participants with overweight or obesity
• Satiety signaling via amylin pathways (Strong preclinical): As a long-acting amylin analog, research suggests cagrilintide engages amylin receptors involved in meal termination and central satiety pathways, similar to endogenous amylin co-secreted with insulin
• Glycemic and metabolic endpoints in type 2 diabetes research (Moderate clinical): Investigational programs have studied effects on glycemic markers and metabolic endpoints in type 2 diabetes and related conditions, including combination regimens with GLP-1 receptor agonists

• Gastrointestinal symptoms — Mild, Common. Clinical trial reports for amylin analogs and CagriSema regimens commonly note nausea, vomiting, and related GI events, consistent with incretin/amylin pathway modulation
• Injection site reactions — Mild, Uncommon. Subcutaneous investigational administration has been associated with local injection-site reactions in trial settings

• Personal or family history of medullary thyroid carcinoma / MEN2 (theoretical class concern) (Theoretical / Preclinical): Although cagrilintide is an amylin analog rather than a pure GLP-1 agonist, combination regimens with semaglutide raise class-related theoretical concerns applied in obesity-drug development frameworks
• Severe gastrointestinal disease (Clinical): Amylin-pathway agents that slow gastric emptying have been researched cautiously in populations with severe GI motility disorders

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT06323161 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin (PHASE3), status: COMPLETED. Indications: Type 2 Diabetes
• NCT05804162 — A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants (PHASE1), status: COMPLETED. Indications: Obesity
• NCT05813925 — A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight (PHASE3), status: COMPLETED. Indications: Obesity or Overweight
• NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight (PHASE3), status: NOT_YET_RECRUITING. Indications: Overweight, Obesity
• NCT03856047 — Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (PHASE2), status: COMPLETED. Indications: Overweight, Obesity
• NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (PHASE3), status: NOT_YET_RECRUITING. Indications: Diabetes Mellitus, Type 2
• NCT07010432 — The Role of the Amylin Analogue Cagrilintide in Bone Metabolism (PHASE1), status: RECRUITING. Indications: Obesity
• NCT06131437 — A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (PHASE3), status: COMPLETED. Indications: Obesity
• NCT06207877 — A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight (PHASE1), status: COMPLETED. Indications: Obesity
• NCT06221969 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (PHASE3), status: ACTIVE_NOT_RECRUITING. Indications: Type 2 Diabetes
• NCT06323174 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (PHASE3), status: COMPLETED. Indications: Type 2 Diabetes
• NCT06719011 — A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (PHASE1), status: RECRUITING. Indications: Obesity, Overweight
• NCT05996848 — A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (PHASE3), status: COMPLETED. Indications: Obesity or Overweight
• NCT07184086 — A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet (PHASE1), status: RECRUITING. Indications: Obesity
• NCT07220642 — Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (PHASE3), status: ACTIVE_NOT_RECRUITING. Indications: Obesity, Overweight
• NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes (PHASE2), status: NOT_YET_RECRUITING. Indications: Diabetes Mellitus, Type 2
• NCT06409130 — Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (PHASE2), status: COMPLETED. Indications: Alcohol-related Liver Disease
• NCT05394519 — A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (PHASE3), status: COMPLETED. Indications: Overweight, Obesity, Type 2 Diabetes Mellitus
• NCT06065540 — A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (PHASE3), status: COMPLETED. Indications: Type 2 Diabetes Mellitus
• NCT07220759 — Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (PHASE3), status: ACTIVE_NOT_RECRUITING. Indications: Overweight, Obesity, Type 2 Diabetes